LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer - Business Wire

LYNPARZA® (olaparib) Reduced the Risk of Disease Progression or Death as First-Line Maintenance Treatment in Germline BRCA-Mutated Metastatic Pancreatic Cancer  Business Wire

AstraZeneca and Merck's LYNPARZA Is the First PARP Inhibitor to Demonstrate Benefit in gBRCAm Metastatic Pancreatic Cancer in a Phase 3 Trial. February ...



Comments

Popular posts from this blog

“A Runner Suddenly Developed Asthma. It Was Stranger Than It Seemed. - The New York Times” plus 1 more

How to perform chest auscultation and interpret the findings - Nursing Times

“National Day Awards 2019, Singapore News & Top Stories - The Straits Times” plus 1 more